share_log

Maxim Group Maintains Buy on Biolase, Lowers Price Target to $1

Benzinga ·  Mar 29, 2023 13:01

Maxim Group analyst Anthony Vendetti maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $5 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment